 Home > Biochemistry News > Biotechnology News > Phase 2 clinical results of innovative bicyclic peptide therapy to improve vision in patients with diabetic macular edema are positive

Phase 2 clinical results of innovative bicyclic peptide therapy to improve vision in patients with diabetic macular edema are positive

 Last Update: 2021-11-05
 Source: Internet
 Author: User

Tags

wasabi america

provera 10 mg

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Recently, Oxurion announced that the THR-149, an investigational therapy jointly developed with Bicycle Therapeutics, has achieved positive results in a phase 2 clinical trial for the treatment of patients with diabetic macular edema (DME)

Macular edema is fluid retention in the macula in the center of the retina

Bicycle's technology platform can screen different types of bicyclic peptides

▲Introduction of THR-149 (picture source: Oxurion official website)

The results of this test show that all dose levels of THR-149 have good safety characteristics, all adverse events are mild to moderate in severity, and no inflammation is observed

▲A visual acuity chart commonly used to test visual acuity (Image source: Jeff Dahl, public domain, Wikimedia commons)

Reference materials:

[1] Positive Phase 2 Part A THR-149 data shared at the America Society of Retina Specialists (ASRS) Annual Scientific Meeting.

(The original text has been deleted)

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Express significantly improves the vision of patients with diabetic macular edema, and the Phase 2 clinical results of the innovative bicyclic peptide therapy are positive

10-21

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.

Phase 2 clinical results of innovative bicyclic peptide therapy to improve vision in patients with diabetic macular edema are positive

Related Articles

Express significantly improves the vision of patients with diabetic macular edema, and the Phase 2 clinical results of the innovative bicyclic peptide therapy are positive